Ruxolitinib improves symptoms and quality of life in myelofibrosis


Tyrosine kinase inhibitors (nibs) and monoclonal antibodies (mabs) are all the rage over the past decade – and they are revolutionising areas of medicine we’ve had no effective treatment for. Myelofibrosis is the latest to be reviewed, with a JAK 1 and 2 inhibitor that’s brand new.

Looking at spleen size, the authors considered a reduction more than 35% as significant – no one in the standard therapy group achieved this, where as over a quarter in the ruxolitinib group did.

The future of myelofibrosis? Pretty likely. Check it out here, in the latest NEJM.


source | NEJM

image | hic et nunc


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s